ReShape Lifesciences 10-Q2017 Q3 Quarterly report

Filed: 14 Nov 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accusing, agreed, alert, Ann, approach, Article, attention, balloon, Black, broader, CA, Canada, Central, Civ, clarify, Clemente, comorbid, contemplated, contracted, Cosmetic, death, Deferral, desired, detected, diligence, dismissing, Distinguishing, diversion, Dual, DUO, element, embedded, esophageal, exceed, experience, False, found, frame, Fulfillium, fundamental, heard, higher, imputed, inability, indefinite, insertion, intragastric, investor, labor, leave, longer, mailed, mandatorily, misappropriation, modified, move, Noncontrolling, Nonpublic, notified, occurrence, opposition, ordinary, perforation, Physician, placement, preclude, Proposal, proposed, published, receipt, redemption, remote, Replacement, Reply, represent, reputational, reshape, retrospective, root, round, San, secret, Secretary, seq, serving, Statute, strike, substantive, Sunshine, symbol, ticker, uncovered, underlying, unforeseen, Uniform, vi, waiver

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ReShape Lifesciences transcripts

ReShape Lifesciences similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Dan W. Gladney, in his capacity as Chief Executive Officer of ReShape Lifesciences Inc., hereby certifies that, to the best of his knowledge:

1.The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 to which this Certification is attached as Exhibit 32.1 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations of ReShape Lifesciences Inc. as of, and for, the periods covered by the Report.


	By:	/S/ DAN W. GLADNEY
		Dan W. Gladney
		President and Chief Executive Officer

Date: November 14, 2017

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.